Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
De-Sheng WangChao RenShan-Shan LiWilliam Pat FongXiao-Jun WuJian XiaoBin-Kui LiYun ZhengPei-Rong DingGong ChenMiao-Zhen QiuZhi-Qiang WangFeng-Hua WangHui-Yan LuoFeng WangXiao-Zhong WangLing-Yun WangDe-Jin XieTao ChenLi-Ren LiZhen-Hai LuXiao-Hui ZhaiTian-Shu LiuYing YuanJia-Qi ChenQiong TanZhi-Zhong PanDe-Sen WanRong ZhangYun-Fei YuanRui-Hua XuYu-Hong LiPublished in: PLoS medicine (2024)
ClinicalTrials.gov Identifier: NCT03493048.